drugset / Trial / NCT00583713

An Open Label Study to Assess the Effect of BLI800 on Safety and Clinical Chemistry Parameters

NCT00583713

Phase 1/2 Completed 18 enrolled Braintree Laboratories
Non-randomizedParallel-groupOpen-labelTreatment

Summary

To evaluate and compare the effects on safety measures and clinical chemistry after BLI800 in two groups of patients and one group of healthy controls. The patient groups will be those with mild or moderate hepatic impairment or moderate renal disease.

Timeline

Start
2007-08
Primary completion
2008-04
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject BLI800 Unknown Oral

Indications

No indication recorded.